NIH TRND Program: Successes in Preclinical Therapeutic Development
| Autor: | Andre M. Pilon, John C. McKew |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Drug Industry Orphan Drug Production Alternative medicine MEDLINE Drug Evaluation Preclinical Business process reengineering Pharmacology Toxicology Commercialization Article Orphan drug Translational Research Biomedical Rare Diseases Drug Discovery medicine Humans business.industry Inherent risk (accounting) Neglected Diseases United States National Institutes of Health (U.S.) Engineering ethics Translational science business |
| Popis: | The Therapeutics for Rare and Neglected D iseases (TRND) program (see: http://ncats.nih.gov/trnd.html) seeks to encourage and speed the development of new treatments for diseases of limited commercial interest to the biopharmaceutical industry. Faced with constrained financial resources and the inherent risk of failure during development, industry must make strategic decisions regarding therapeutic commercialization [1, 2]. Often, “rare” diseases of low prevalence, as defined in the Orphan Drug Act, as amended [3, 4], as well as high-prevalence “neglected” diseases (see: http://www.who.int/neglected_diseases/diseases/en/) occurring chiefly among impoverished populations in the developing world go unaddressed. Part of the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health (NIH), TRND represents an important aspect of the NIH commitment to improving health through basic biomedical research and reengineering translational science [5]. TRND contributes to this effort by stimulating collaborations among intramural NIH scientists and extramural academic researchers, nonprofit organizations, and pharmaceutical and biotechnology companies actively developing therapeutic candidates for rare or neglected disease (RND) indications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|